Pharm-Olam and CATO-SMS have merged. Learn More
Because of our late phase and post-marketing expertise, Pharm-Olam has the capabilities and services needed to support your needs fully. We provide the following late phase and post-marketing services:
Pharm-Olam works to support your late phase and post-marketing study by providing ecosystems of therapeutically-aligned, cross-functional teams. These experts enhance and underscore our capabilities as well as our service offerings by creating synergies and efficiencies that help your study reach its goals and milestones. Our areas of focus include the following therapeutic areas:
Our dedicated team of cancer researchers creates solutions and provides consultations focused on the needs of your sites and patients — all while helping to save your study time and money.
Our infectious disease and vaccine site networks are dedicated to supporting this critical area of research in every area from immunizations to immunotherapy.
With more than 100 rare disease clinical trials completed, we provide the expertise and experience to meet the unique challenges of these studies.
We understand that allergy clinical trials and asthma clinical studies require present a variety of unique challenges that our Allergy CRO team is well-equipped to handle.
Pharm-Olam has the expertise, investigator relationships, and supportive technology to effectively deliver autoimmune clinical research studies.
Our U.S.-based team has worked for more than 30 years within the post-marketing and medical information area. Our impeccable record of service includes multiple successful FDA audits with zero findings in support of post-marketing and medical information activities.
Some of our services include:
For a full-list of our services in support of your post-marketing safety requirements, please see our Pharmacovigilance and Medical Information page.
